×
About 28,398 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  8,349 results

Measurable residual disease in acute lymphoblastic leukemia: methods and clinical conte...
https://doi.org/10.3324/haematol.2022.280638
Haematologica Saygin C, Cannova J et. al.

Dec 2nd, 2022 - Measurable residual disease (MRD) is the most powerful independent predictor of risk of relapse and long-term survival in adults and children with acute lymphoblastic leukemia (ALL). For almost all patients with ALL there is a reliable method to e...

Osteoarticular manifestation of acute lymphoblastic leukemia in adults: a literature re...
https://doi.org/10.1007/s10067-022-06459-7
Clinical Rheumatology; Slouma M, Hannech E et. al.

Dec 2nd, 2022 - Osteoarticular manifestations such as arthritis and bone pain are scarce among adults with acute lymphoblastic leukemia (ALL). We present a systematic review of osteoarticular first clinical manifestation related to ALL in adults, and we report a ...

UBTF-Internal tandem duplication as a novel poor prognostic factor in pediatric acute m...
https://doi.org/10.1002/gcc.23110
Genes, Chromosomes & Cancer; Kaburagi T, Shiba N et. al.

Dec 1st, 2022 - The prognosis of pediatric acute myeloid leukemia (AML) has improved via stratification therapy. However, relapse or death occurs in 30%-40% of cases. Novel genetic factors for pediatric AML need to be elucidated to improve prognosis. We detected ...

A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous inf...
https://doi.org/10.1002/cncr.34570
Cancer Boddu PC, Senapati J et. al.

Dec 1st, 2022 - Nelarabine is a purine nucleoside analogue prodrug approved for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) and lymphoblastic lymphoma (T-LBL). Although effective in R/R T-ALL, significant neurotoxicity...

Somatic TP53 mutations are pre-leukemic events in acute lymphoblastic leukemia.
https://doi.org/10.1182/blood.2022017249
Blood Chitadze G, Stengel A et. al.

Dec 1st, 2022 - Somatic TP53 mutations are pre-leukemic events in acute lymphoblastic leukemia.|2022|Chitadze G,Stengel A,John-Klaua C,Bruckmüller J,Trautmann H,|

see more →

Guidelines  4 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.

Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...

Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment...
https://doi.org/10.1016/j.bbmt.2011.12.585
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.

Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...

see more →

Drugs  130 results see all →

Clinicaltrials.gov  951 results

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
https://clinicaltrials.gov/ct2/show/NCT02828358

Oct 14th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the tolerability of azacitidine in addition to Interfant-06 standard chemotherapy in infants with newly diagnosed acute lymphoblastic leukemia (ALL) with KMT2A gene rearrangement (KMT2A-R). SECONDARY OBJECTIVE: I....

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03739814

Oct 14th, 2022 - PRIMARY OBJECTIVES: I. To confirm tolerability of the combination regimen of inotuzumab ozogamicin followed by blinatumomab. II. To estimate the 1-year event-free survival of older, transplant-ineligible patients with newly diagnosed, Philadelphia...

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT02315612

Oct 14th, 2022 - Background: Adoptive cellular therapy with T cells genetically modified using viral-based vectors to express chimeric antigen receptors targeting the CD19 molecule have demonstrated dramatic clinical responses in patients with acute lymphoblastic ...

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymp...
https://clinicaltrials.gov/ct2/show/NCT04994717

Oct 14th, 2022 - The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of part...

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
https://clinicaltrials.gov/ct2/show/NCT02390752

Oct 14th, 2022 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...

see more →

News  1,917 results

Neurologic Symptoms Linked With Death in Pediatric Leukemia
https://www.medscape.com/viewarticle/984925

Dec 2nd, 2022 - Neurologic manifestations such as headache, neuropathy, seizures, and cell infiltration are common in pediatric patients with acute leukemia and are associated with a higher mortality rate, according to a retrospective, analytic, longitudinal stud...

Lung Screening Saves Lives; Clues to Hyperprogression; Bacteria Foil Immunotherapy
https://www.medpagetoday.com/hematologyoncology/lungcancer/101912

Nov 25th, 2022 - Diagnosis of early-stage lung cancer with low-dose CT screening was associated with significant improvement in long-term survival. (Mount Sinai, Radiological Society of North America) Researchers have discovered how cancer immunotherapy sometimes ...

Dr. Jabbour on MRD Testing in B-ALL
https://www.onclive.com/view/dr-jabbour-on-mrd-testing-in-b-all

Nov 23rd, 2022 - Elias Jabbour, MD, professor, the Department of Leukemia, the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of testing for minimal residual disease (MRD) when determining optimal treatment...

FDA Approves Additional Dosing Schedule for Rylaze in ALL and LBL
https://www.onclive.com/view/fda-approves-additional-intramuscular-dosing-schedule-for-rylaze-in-all-and-lbl

Nov 18th, 2022 - The FDA has approved a supplemental biologics license application to add a Monday/Wednesday/Friday (MWF) intramuscular dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze).1 In June 2021, Rylaze was approved for use a...

Ponatinib Provides Higher Rate of MRD-negative CR Vs Imatinib in Newly Diagnosed Ph+ ALL
https://www.onclive.com/view/ponatinib-provides-higher-rate-of-mrd-negative-cr-vs-imatinib-in-newly-diagnosed-ph-all

Nov 17th, 2022 - Ponatinib (Iclusig) plus reduced-intensity chemotherapy produced a higher rate of minimal residual disease (MRD)–negative complete remission compared with imatinib (Gleevec) in patients with newly diagnosed Philadelphia chromosome (Ph)–positive ac...

see more →

Patient Education  8 results see all →